CEBPA and chronic myelogenous leukemia, BCR-ABL1 positive: CEBPA upregulates the expression of the lncRNA PLIN2, and PLIN2 promotes the occurrence and development of CML by upregulating the expression of β-catenin, providing a theoretical basis for targeting the CEBPA/PLIN2 axis for the treatment of CML [74].